Evidence map›Paper›PMID 39240546›Full record

ArticleChemMedChem2025

Enhancing Flucytosine Anticandidal Activity Using PEGylated Squalene Nanocarrier.

Bogdan-Florin Craciun, Irina Rosca, Dragos Peptanariu, Mariana Pinteala

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ChemMedChem, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Bogdan-Florin CraciunCentre of Advanced Research in Bionanoconjugates and Biopolymers, "Petru Poni", Institute of Macromolecular Chemistry, 41 A Grigore Ghica Voda Alley, Iasi, 700487, Romania.ORCID https://orcid.org/0000-0002-2324-0088
Irina RoscaCentre of Advanced Research in Bionanoconjugates and Biopolymers, "Petru Poni", Institute of Macromolecular Chemistry, 41 A Grigore Ghica Voda Alley, Iasi, 700487, Romania.ORCID https://orcid.org/0000-0003-3080-1709
Dragos PeptanariuCentre of Advanced Research in Bionanoconjugates and Biopolymers, "Petru Poni", Institute of Macromolecular Chemistry, 41 A Grigore Ghica Voda Alley, Iasi, 700487, Romania.ORCID https://orcid.org/0000-0001-8108-3765
Mariana PintealaCentre of Advanced Research in Bionanoconjugates and Biopolymers, "Petru Poni", Institute of Macromolecular Chemistry, 41 A Grigore Ghica Voda Alley, Iasi, 700487, Romania.ORCID https://orcid.org/0000-0002-4021-982X

Funding

Unitatea Executiva pentru Finantarea Invatamantului Superior, a Cercetarii, Dezvoltarii si Inovarii PN-III-P1-1.1-PD-2021-0606
6 · The paper itself

Abstract

There is an emerging necessity for improved therapies against Candida-related infections, with significant implications for global healthcare. Current antifungal agents, limited in number, target specific pathways, but resistance remains a concern. Flucytosine (5FC) exhibits antifungal activity, particularly against Candida. However, monotherapy efficacy is limited, necessitating combination treatments. Herein, we report PEGylated squalene-based nanocarriers for 5FC loading, aiming to enhance its monotherapy efficacy against Candida strains. The loading of 5FC within micelles was achieved using the ultrasound-assisted solvent evaporation method. The 5FC-loaded micelles, together with non-loaded micelles, were thoroughly characterized and analyzed. STEM and DLS analysis confirmed the core-shell morphology with nanometric dimensions along with improved colloidal stability. The quantification of drug loading efficiency and drug loading capacity was calculated using the UV-Vis technique. The in vitro drug-release studies in simulated physiological conditions showed sustained release within 48 hours. Moreover, the release kinetics calculated using mathematical models showed a Fickian diffusion drug release mechanism in simulated physiological conditions with a slower diffusion rate. The in vitro antifungal activity was tested on Candida albicans, Candida glabrata, and Candida parapsilosis. The results showed improved antifungal activity for the nanotherapeutic and unchanged in vitro toxicity toward normal cells, suggesting promising advancements in 5FC therapy.

Indexed as

Antifungal AgentsCandida albicansDrug CarriersFlucytosineMicrobial Sensitivity TestsNanoparticlesPolyethylene GlycolsSqualeneCandidaCandida glabrataCell SurvivalDose-Response Relationship, DrugDrug LiberationHumansMicellesMolecular StructureAntifungal AgentsDrug CarriersFlucytosineMicellesPolyethylene GlycolsSqualeneAntifungal activityCandida infectionsDrug deliveryFlucytosineMicelles

Identifiers

PMID39240546
PMCPMC11694607

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.